Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective

Resource type
Journal Article
Authors/contributors
Title
Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective
Abstract
Invasive fungal disease (IFD) remains a significant cause of morbidity and mortality in children undergoing transplantation. There is a growing armamentarium of novel antifungal agents recently approved for use or in late stages of clinical development. The overarching goal of this review is to discuss the mechanisms of action, spectrum of activity, stage of development, and pediatric-specific data for the following agents: encochleated amphotericin B deoxycholate, fosmanogepix, ibrexafungerp, isavuconazole, olorofim, opelconazole, oteseconazole, and rezafungin. Additionally, key drug attributes of these novel agents and their potential future therapeutic roles in pediatric transplant recipients are discussed.
Publication
Journal of the Pediatric Infectious Diseases Society
Volume
13
Issue
Supplement_1
Pages
S68-S79
Date
2024-02-01
Journal Abbr
Journal of the Pediatric Infectious Diseases Society
ISSN
2048-7207
Short Title
Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients
Accessed
3/17/24, 10:21 AM
Library Catalog
Silverchair
Citation
Hsu, A. J., Hanisch, B. R., Fisher, B. T., & Huppler, A. R. (2024). Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective. Journal of the Pediatric Infectious Diseases Society, 13(Supplement_1), S68–S79. https://doi.org/10.1093/jpids/piad115
DRUGS AND THERAPIES
SOLID ORGANS AND MCSS
Link to this record